Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Simcere Sells Celgen Stake for $49 Million

publication date: Jan 23, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma has sold its 35% stake in Shanghai Celgen Bio-Pharmaceutical for 302 million RMB ($48.6 million). That’s more than twice the $20.6 million Simcere paid for the shares in 2009. Celgen makes a biosimilar version of arthritis treatment etanercept. Simcere sold its shares to Devont Asset Management Limited without disclosing a reason for the sale. More details....

Stock Symbol: (NYSE: SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners